Boehringer Ingelheim and Enara Bio Enter Strategic Collaboration and Licensing Agreement to Discover Novel Shared Antigens for Cancer Immunotherapies
Boehringer Ingelheim and Enara Bio, today announced that they have entered into a strategic collaboration and licensing agreement to research and develop novel targeted cancer immunotherapies, leveraging Enara Bio’s Dark Antigen™ discovery platform. This new collaboration combines Boehringer Ingelheim’s approach to tackle cancer through pairing leading science with innovative immune-oncology platforms, such as oncolytic viruses and cancer vaccines, with Enara Bio’s expertise in cancer antigen identification. The aim is to provide potential new therapies for patients with difficult to treat lung and gastrointestinal cancers.
“We are excited to partner with Enara Bio as part of our mission to bring transformative new treatments to cancer patients,” said Jonathon Sedgwick, Ph.D., Senior Vice President and Global Head, Cancer Immunology & Immune Modulation Research, Boehringer Ingelheim. “We are advancing a unique pipeline of cancer cell-directed agents, immuno-oncology therapies and intelligent combination approaches to help combat cancer. Enara Bio’s unique discovery platform offers a novel and highly differentiated approach that will allow us to look beyond the known proteome to identify and characterize Dark Antigens to support the development of T-Cell Receptor (TCR)-directed immunotherapies and therapeutic vaccines. We believe this is a highly innovative and promising approach to the development of the next wave of cancer immunotherapies.”
Enara Bio’s proprietary Dark Antigen Platform Technology (EDAPT™) will be used to discover and validate novel Dark Antigens in up to three tumor types in the lung and gastrointestinal cancer space. The discovery of shared antigens could lead to the development of vaccines that can be readily utilized to help a broader group of cancer patients.
Dark Antigens represent a new class of cancer-associated antigens that derive from the genomic dark matter, or the portion of the human genome that is normally not expressed as protein. Dark Antigen-encoding sequences are usually silenced in healthy cells but are activated and presented on tumor cells. They are associated with specific cancer types and, importantly, are shared across patients. Since typically not visible to the immune system, they represent a large potential repertoire of novel antigens that can be developed as targets for new immunotherapies.
“We are extremely pleased to enter this strategic licensing agreement, our first major deal leveraging our pioneering Dark Antigen discovery and validation capabilities,” said Kevin Pojasek, President and CEO of Enara Bio. “Boehringer Ingelheim is an innovation-led company dedicated to producing breakthrough treatments with a significant focus on cancer. We are excited to build this relationship and are encouraged that Boehringer Ingelheim shares our view of the potential of Dark Antigens to be a source of important and unconventional targets for novel cancer immunotherapies. This agreement provides strong validation for our science and our approach to exploiting the cancer-associated antigenic repertoire derived from genomic dark matter and we look forward to a productive collaboration.”
This collaboration with Enara Bio is the latest of several strategic partnerships and acquisitions for Boehringer Ingelheim to build its cancer vaccine platform and provides important validation for Enara Bio’s Dark Antigen platform. The past acquisitions of ViraTherapeutics and AMAL Therapeutics’ vaccine modalities coupled with Enara Bio’s capabilities position Boehringer Ingelheim to develop sophisticated virus and vaccine modalities for its prime/boost vaccine platform.
Under the agreement, Boehringer Ingelheim has the option to license Dark Antigens discovered and validated by Enara Bio. Boehringer Ingelheim will also be responsible for all non-clinical and clinical development, as well as commercialization of associated cancer immunotherapies, including therapeutic vaccines and T-cell redirecting biologics. Enara Bio retains rights to use any discovered antigens for use in cell therapy-based products.
Enara Bio is eligible to receive an upfront payment, together with research/preclinical milestones and licensing fees for each tumor type that is explored. Enara Bio is also eligible to receive more than EUR 876 million in clinical, regulatory and commercial milestones, in addition to royalties on future product sales.
Please click on the following link for ‘Notes to Editors’:
http://www.boehringer-ingelheim.com/press-release/strategic-collaboration-enarabio
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210112005444/en/
Contact information
Media Contacts
Boehringer Ingelheim
Dr. Reinhard Malin
Head of Communications Innovation Unit
Boehringer Ingelheim Corporate Center GmbH
Media + PR
P: 49 6132 77-90815
press@boehringer-ingelheim.com
Linda Ruckel
Senior Associate Director, Media and Corporate Reputation
Boehringer Ingelheim U.S.
Media + PR
P: 203-791-6672
press@boehringer-ingelheim.com
Enara Bio
Enara Bio Limited
Kevin Pojasek, CEO
P: +44(0)1865 504 994
info@enarabio.com
Citigate Dewe Rogerson
Mark Swallow, Frazer Hall, Nathaniel Dahan
P: +44 (0)20 7638 9571
enarabio@citigatedewerogerson.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Boomi Named a 2025 Geo and Global AWS Partner Award Finalist8.12.2025 16:00:00 EET | Press release
Boomi™, the leader in AI-driven automation, today announced it is a finalist for a 2025 Geography and Global AWS Partner Award, recognizing leaders around the globe that are playing key roles in helping their customers drive innovation and build solutions on Amazon Web Services (AWS). Boomi is excited to announce it has been named a finalist for Rising Star Partner of the Year (Technology), which honors the top AWS Partner that has seen significant year-over-year growth in their Technology business. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251208700959/en/ Boomi Named a 2025 Geo and Global AWS Partner Award Finalist The Geography and Global AWS Partner Awards recognize a wide range of AWS Partners that have embraced specialization, innovation, and cooperation over the past year. Geo and Global AWS Partner Awards commend partners whose business models continue to evolve and thrive on AWS as they support their customers.
iFIT and F45 Training Announce Global Partnership to Bridge Digital and Studio Fitness8.12.2025 16:00:00 EET | Press release
iFIT, a global leader in connected fitness, content, and equipment, and F45 Training, a leading global fitness community and franchise, today announced a new global partnership that will redefine the member experience by seamlessly integrating at-home digital training with in-studio community fitness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251208170773/en/ Launching December 8, the collaboration combines F45 Training’s world-class, high-intensity functional training methodology with iFIT’s immersive workout production capabilities and expansive global platform. Integrated Fitness Collaboration This strategic partnership is built on two key pillars designed to drive engagement for both platforms: Premium Digital Content Access: iFIT will license and feature a curated collection of F45 Training’s signature functional, at-home workouts on its global streaming platform. This immediately brings F45’s acclaimed, results-dr
PHOTRON LIMITED Announces Acquisition of AOS Technologies AG8.12.2025 16:00:00 EET | Press release
PHOTRON LIMITED, a global leader in high-speed and scientific imaging solutions, today announced its acquisition of AOS Technologies AG, a Swiss-based designer and manufacturer of advanced high-speed imaging systems serving automotive, aerospace, industrial, and defense markets. Founded in 2002, AOS Technologies has earned worldwide recognition for its engineering innovation, rugged imaging platforms, and application expertise. The acquisition strengthens PHOTRON’s global strategy to expand technical capabilities, accelerate innovation, and grow its presence across high-performance imaging markets. “AOS Technologies brings engineering depth and a strong product portfolio that is complementary to PHOTRON’s long-term vision,” said Takashi Takimizu, President of PHOTRON LIMITED. “As PHOTRON continues to strengthen its growth strategy through targeted M&A activity and strategic business alliances, this partnership reflects our commitment to building a broader, more innovative global imagin
Guidewire Olos Release Powers Intelligent Pricing, Drives Faster Rate Changes, and Enhances Workers’ Compensation Performance8.12.2025 15:55:00 EET | Press release
Guidewire (NYSE: GWRE) today announced Olos, its latest release, designed to help P&C insurers modernize their pricing strategies, accelerate rate changes, optimize underwriting processes, and strengthen workers’ compensation performance. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251208759369/en/ Faster, Smarter Pricing and Rating with Guidewire PricingCenter Guidewire PricingCenter unifies the entire pricing and rating lifecycle, eliminating manual handoffs across actuarial, pricing, and IT teams. The platform supports dynamic price modeling and impact analysis, AI-assisted pricing insights, as well as seamless integration with other Guidewire applications and services, enabling faster rate changes and greater agility. “PricingCenter gives insurers a single platform to model, test, and deploy pricing changes with speed and confidence,” said Dawid Kopczyk, Senior Director, Pricing and Rating, Guidewire. “By unifying wor
BRUKINSA Delivers Landmark 74% 6-Year PFS in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia8.12.2025 15:00:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, reaffirms its position as the leader in chronic lymphocytic leukemia (CLL) innovation by showcasing the depth, quality, and momentum of its hematology portfolio at the 67th ASH Annual Meeting and Exposition in Orlando, Florida. The totality of BeOne’s ASH data reinforce BRUKINSA® (zanubrutinib) as the foundational Bruton’s tyrosine kinase inhibitor (BTKi) of choice. “At ASH 2025, we will present new data from across our CLL franchise, highlighting both the strength of BRUKINSA and the potential of BGB-16673,” said Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne. “Long-term data are the gold standard in CLL, and BRUKINSA continues to deliver the high levels of durable progression-free and overall survival that patients and physicians should demand from a BTK inhibitor. BGB-16673, the most advanced BTK degrader in the clinic with over 800 patients dosed to date, potentially repres
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom